5-150124275-G-T
Variant summary
Our verdict is Pathogenic. Variant got 20 ACMG points: 20P and 0B. PS1PM2PM5PP3_StrongPP5_Very_Strong
The NM_002609.4(PDGFRB):c.1998C>A(p.Asn666Lys) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Pathogenicin Lovd. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N666H) has been classified as Pathogenic.
Frequency
Consequence
NM_002609.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PDGFRB | NM_002609.4 | c.1998C>A | p.Asn666Lys | missense_variant | 14/23 | ENST00000261799.9 | NP_002600.1 | |
PDGFRB | NM_001355016.2 | c.1806C>A | p.Asn602Lys | missense_variant | 13/22 | NP_001341945.1 | ||
PDGFRB | NM_001355017.2 | c.1515C>A | p.Asn505Lys | missense_variant | 14/23 | NP_001341946.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PDGFRB | ENST00000261799.9 | c.1998C>A | p.Asn666Lys | missense_variant | 14/23 | 1 | NM_002609.4 | ENSP00000261799 | P1 | |
PDGFRB | ENST00000520579.5 | c.*1312C>A | 3_prime_UTR_variant, NMD_transcript_variant | 14/23 | 1 | ENSP00000430026 | ||||
PDGFRB | ENST00000520229.1 | n.633C>A | non_coding_transcript_exon_variant | 2/2 | 3 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Myofibromatosis, infantile, 1 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | research | Lupski Lab, Baylor-Hopkins CMG, Baylor College of Medicine | Feb 12, 2013 | This mutation has been found in two myofibromas from one of the affected familial cases. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Seattle Children's Hospital Molecular Genetics Laboratory, Seattle Children's Hospital | Jan 21, 2022 | The PDGFRB p.Asn666Lys variant has been previously reported in the somatic state in multiple patients with infantile myofibromatosis (OMIM #228550) (PMID: 28334876 and others). The p.Asn666Lys variant is in the N-terminal lobe of the kinase domain of the PDGFRB protein and results in constitutive activation of downstream signaling (PMID: 28334876). This variant was identified in 35% of reads, suggesting somatic origin. Although the p.Asn666Lys variant has only been reported in the somatic state, constitutional activating variants in PDGFRB have been previously reported (PMID: 28334876 and others). - |
Infantile myofibromatosis Pathogenic:1
Pathogenic, criteria provided, single submitter | research | Demoulin lab, University of Louvain | Feb 01, 2017 | This mutation was found in two patients with myofibromatosis in our cohort and has been reported by others. It strongly activates PDGFRB signaling in cell culture (gain of function). It was associated with other mutations in the same gene: in one patient, it was associated with c.1696T>C (p.W566R) and in a second case, with c.1681C>T (p.R561C). Another variant, c.1998C>G, leads to the same amino acid change (p.N666K). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at